1 completed, 1 recruiting, 1 unknown. 3 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 1, Recruiting 1, Unknown 1 |
| Phase 2 | 1 | Completed 1 |
Follow Progression Free Survival: new trials by email Literature Review of Progression Free Survival trials Research Report on Progression Free Survival
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Survival With Olanzapine in Patients With Locally Advanced or Metastatic Upper Gastrointestinal and Lung Cancer Olanzapine 2.5 MG, Standard anti-tumor treatment, Nutritional advice - Advanced Cancer, Olanzapine | Phase 3 | Recruiting | Qinghai Red Cross Hospital | 230 | 2024-03-20 | 2024-03-29 |
| A Study of Standard Treatment +/- Apatinib in Extensive Stage Small Cell Lung Cancer cisplatin, etoposide, cisplatin, etoposide, apatinib - Progression Free Survival | Phase 3 | Unknown | Qingdao University | 120 | 2017-03-01 | 2017-04-04 |
| Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung Cancer Osimertinib, docetaxel, bevacizumab - Progression Free Survival | Phase 2 / Phase 3 | Completed | Qingdao Central Hospital | 147 | 2015-08-01 | 2018-02-14 |
Bevacizumab (1) · Cisplatin (1) · Docetaxel (1) · Etoposide (1) · Olanzapine (1) · PE regimen (1) · apatinib (1) · osimertinib (1)
Qingdao Central Hospital (1) · Qingdao University (1) · Qinghai Red Cross Hospital (1)
China (3)